IVERIC bio Inc

IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced the early completion of patient enrollment of GATHER2, the Company's 2nd pivotal clinical trial of Zimura® (avacincaptad pegol).

Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura® Ahead of Schedule

GT Biopharma Inc

NRX Pharmaceuticals

Penny Stocks & Small Caps Jump As Biotech Industry Names Kick Into High Gear The post Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced today the appointment of Christopher Simms to Senior Vice President and Chief Commercial Officer, effective August 2, 2021.

Iveric Bio Appoints Christopher Simms as Chief Commercial Officer

IVERIC bio (ISEE) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

IVERIC bio (ISEE) Enters Overbought Territory

Iveric bio Inc (NASDAQ: ISEE) priced its underwritten public offering of 11.6 million shares at $8.60 per share, representing a discount of 4.6% from the last close price of $9.01 on Monday. Underwriters have an option to purchase up to an additional 1.7 million shares.

Iveric Bio Raises $100M Via Equity To Fund Zimura Development In Geographic Atrophy

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced the pricing of an underwritten public offering of 11,650,000 shares of its common stock.

IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that it is commencing an underwritten public offering of shares of its common stock.

IVERIC bio, Inc. Announces Proposed Offering of Common Stock

Investors need to pay close attention to IVERIC bio (ISEE) stock based on the movements in the options market lately.

Do Options Traders Know Something About IVERIC bio (ISEE) Stock We Don't?

The stock price of IVERIC bio Inc (NASDAQ: ISEE) increased by 11.87%. This is why it happened.

IVERIC bio Stock Increased 11.87%: Why It Happened

Iveric Bio Inc (NASDAQ: ISEE) has received written agreement from the FDA under a Special Protocol Assessment (SPA) for the overall design of the GATHER2 trial of Zimura (avacincaptad pegol) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).  As previously announced, the Company expects to complete enrollment in GATHER2 in late July.

Iveric Bio Stock Jumps Higher On SPA Agreement From FDA For Zimura Study In Geographic Atrophy

The stock price of IVERIC bio Inc (NASDAQ: ISEE) increased by over 30% pre-market. This is why it happened.

ISEE Stock Price Increases Over 30% Pre-Market: Why It Happened

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that the Company received written agreement from the US FDA under a Special Protocol Assessment (SPA) for the design of GATHER2.

Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration

Iveric Bio Inc (NASDAQ: ISEE) has shared the new post-hoc analyses of GATHER1 and the progress of GATHER2 clinical trials evaluating Zimura (avacincaptad pegol) for geographic atrophy (G.A.) secondary to age-related macular degeneration (AMD).

Iveric Bio Reveals Positive Post-Hoc Analyses Of Zimura In Dry Age-Related Macular Degeneration

NEW YORK--(BUSINESS WIRE)--Iveric Bio will present data on Zimura GATHER2 and new GATHER1 post-hoc analyses at its Dry Age-Related Macular Degeneration Virtual Symposium.

Iveric Bio to Present Zimura® GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyses Today at its Dry Age-Related Macular Degeneration Virtual Symposium for Investors

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced details for its Dry Age-Related Macular Degeneration Virtual Symposium on June 18, 2021, from 10:00 a.m. to 12:00 p.m. ET.

Iveric Bio to Host Investor Symposium on Dry Age-Related Macular Degeneration on June 18, 2021

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2021 Results - Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced financial and operating results for the quarter ended March 31, 2021 and provided a general business update.

Iveric Bio Reports First Quarter 2021 Operational Highlights and Financial Results

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that it will report its first quarter 2021 financial and operating results on Wednesday, May 5, 2021.

Iveric Bio to Report First Quarter 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021

NEW YORK--(BUSINESS WIRE)--Iveric Bio today announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years.

David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q4 2020 Results - Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced financial and operating results for the fourth quarter and full year ended Dec. 31, 2020 and provided a general business update.

Iveric Bio Reports Fourth Quarter and Year End 2020 Operational Highlights and Financial Results

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that Glenn Sblendorio, CEO, and Pravin Dugel, CSO, CBO, will participate in a fireside chat at the Cowen Conference on March 4.

Iveric Bio to Present at the Cowen 41st Annual Health Care Conference

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced that it will report its fourth quarter and full year 2020 financial and operating results on Wednesday, March 3, 2021.

Iveric Bio to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Wednesday, March 3, 2021

NEW YORK--(BUSINESS WIRE)--IVERIC bio announced that Glenn P. Sblendorio, CEO and President, will present at the 39th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2021.

IVERIC bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2020 Results - Earnings Call Transcript

News for IVERIC bio Inc Stock (ISEE)